{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"The number of suspicious lesions will be identified by uptake of F18 FDOPA radiopharmaceutical using a positron emission tomography (PET) scan. Uptake of F-18 FDOPA is a measure of amino acid uptake and metabolism in tumors. Suspicious lesions will be visually identified by a board certified nuclear medicine physician.","groups":[{"description":"Patients receive 18F-FDOPA intravenously (IV) and then undergo PET/CT or PET/MRI 10-30 minutes later. After completion of study, patients are followed up at 24 hours and at 1 week.","id":"OG000","title":"Diagnostic (FDOPA-PET/CT or PET/MRI)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 30 minutes after injection of F18 FDOPA","title":"Number of Suspicious Lesions Identified by 18F FDOPA PET","type":"PRIMARY","unitOfMeasure":"suspicious lesion(s)"}